CA2699787A1 - (3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating - Google Patents

(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating Download PDF

Info

Publication number
CA2699787A1
CA2699787A1 CA2699787A CA2699787A CA2699787A1 CA 2699787 A1 CA2699787 A1 CA 2699787A1 CA 2699787 A CA2699787 A CA 2699787A CA 2699787 A CA2699787 A CA 2699787A CA 2699787 A1 CA2699787 A1 CA 2699787A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
solvate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2699787A
Other languages
English (en)
French (fr)
Inventor
Arun K. Ghosh
Chunfeng Liu
Thippeswamy Devasamudram
Hui Lei
Lisa M. Swanson
Sudha V. Ankala
John C. Lilly
Geoffrey M. Bilcer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
CoMentis Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2699787A1 publication Critical patent/CA2699787A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2699787A 2007-09-24 2008-09-24 (3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating Abandoned CA2699787A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97479307P 2007-09-24 2007-09-24
US60/974,793 2007-09-24
PCT/US2008/077537 WO2009042694A1 (en) 2007-09-24 2008-09-24 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating

Publications (1)

Publication Number Publication Date
CA2699787A1 true CA2699787A1 (en) 2009-04-02

Family

ID=40343545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699787A Abandoned CA2699787A1 (en) 2007-09-24 2008-09-24 (3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating

Country Status (8)

Country Link
US (1) US8299267B2 (enExample)
EP (1) EP2205596A1 (enExample)
JP (1) JP5055432B2 (enExample)
KR (1) KR20100059919A (enExample)
CN (1) CN101868457B (enExample)
CA (1) CA2699787A1 (enExample)
MX (1) MX2010002938A (enExample)
WO (1) WO2009042694A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002938A (es) 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
US8377973B2 (en) * 2009-09-04 2013-02-19 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP2013506713A (ja) * 2009-10-05 2013-02-28 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US20120053200A1 (en) * 2010-09-01 2012-03-01 Harald Mauser Bace 2 inhibitors
CN104781257A (zh) 2012-06-14 2015-07-15 第一三共株式会社 哌啶基吡唑并吡啶衍生物
CN105669365B (zh) * 2016-03-04 2022-06-21 中国科学院上海有机化学研究所 含二氟烷基取代的芳基或杂芳基化合物、制备方法和应用
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN110117237B (zh) * 2018-02-05 2024-02-02 中国科学院上海有机化学研究所 一种芳香腈或烯基腈类化合物的制备方法
CN110642789B (zh) * 2019-11-25 2020-05-26 天津凯莱英制药有限公司 2-氯嘧啶-4-甲酸类化合物的连续性合成方法
CN112321515A (zh) * 2020-10-21 2021-02-05 上海馨远医药科技有限公司 一种手性1-叔丁基-3-甲基-6-甲基哌嗪-1,3-二甲酸酯的制备方法
US20250115636A1 (en) * 2022-02-03 2025-04-10 Purdue Research Foundation Peptidomimetic inhibitors of protein n-terminal methyltransferase 1, composition, and method of use
US12191004B2 (en) 2022-06-27 2025-01-07 Microsoft Technology Licensing, Llc Machine learning system with two encoder towers for semantic matching

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
TW282460B (enExample) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5728718A (en) 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
AU5773500A (en) 1999-06-28 2001-01-31 Board Of Trustees Of The University Of Illinois, The Inhibitors of memapsin 2 and use thereof
JP4850379B2 (ja) 1999-12-16 2012-01-11 エミスフェアー・テクノロジーズ・インク 活性剤を輸送するための化合物及び組成物
JP2004528266A (ja) 2000-04-12 2004-09-16 インプリクス リミテッド 薬物送達用組成物
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
EP1299352B1 (en) 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
AU2002239727C1 (en) 2000-12-28 2005-12-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
US20060234944A1 (en) 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
JP4547152B2 (ja) 2001-10-23 2010-09-22 オクラホマ メディカル リサーチ ファウンデーション β−セクレターゼ阻害剤および使用方法
EA200400648A1 (ru) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
BR0214736A (pt) 2001-12-06 2004-11-23 Elan Pharm Inc Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições
CA2477607A1 (en) 2002-02-27 2003-09-04 Pharmacia & Upjohn Company Substituted hydroxyethylamines
AU2003220115A1 (en) 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2004022523A2 (en) 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
WO2004043916A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0305918D0 (en) 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
JP4448134B2 (ja) 2003-08-08 2010-04-07 シェーリング コーポレイション ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
EP1697308B1 (en) 2003-12-19 2014-03-19 Merck Sharp & Dohme Corp. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
JP2008502684A (ja) 2004-06-15 2008-01-31 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病を治療するためのベータ−セクレターゼ阻害剤として有用なピロリジン−３−イル化合物
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
EP1797052A1 (en) * 2004-09-17 2007-06-20 Comentis, Inc. Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
US7659289B2 (en) 2004-09-17 2010-02-09 Comentis, Inc. Hydroxyethylene-based β-secretase inhibitors and use thereof
CN100475786C (zh) * 2005-02-18 2009-04-08 中国科学院上海药物研究所 一类4-羟基戊酰胺类化合物及其制备方法和用途
US7745470B2 (en) 2005-03-10 2010-06-29 Bristol-Myers Squibb Company Isophthalates as beta-secretase inhibitors
JP2008535863A (ja) 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR054044A1 (es) 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
AR054363A1 (es) 2005-05-23 2007-06-20 Astrazeneca Ab Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US7476764B2 (en) 2005-08-04 2009-01-13 Bristol-Myers Squibb Company Phenylcarboxyamides as beta-secretase inhibitors
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
EP2077719B1 (en) 2006-09-21 2011-12-28 Merck Sharp & Dohme Corp. Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
CA2697166A1 (en) 2007-07-26 2009-01-29 Comentis, Inc. Isophthalamide derivatives inhibiting betasecretase activity
MX2010002938A (es) 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
WO2010002994A1 (en) 2008-07-01 2010-01-07 Purdue Research Foundation Nonpeptide hiv-1 protease inhibitors
EP2349308A4 (en) 2008-10-10 2012-09-12 Purdue Research Foundation COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2010042892A1 (en) 2008-10-10 2010-04-15 Comentis, Inc. Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
EP2376083A4 (en) 2008-11-20 2012-06-20 Purdue Research Foundation QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
WO2010065861A2 (en) 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
CA2756145A1 (en) 2009-03-25 2010-09-30 Purdue Research Foundation Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
JP2013506713A (ja) 2009-10-05 2013-02-28 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法

Also Published As

Publication number Publication date
JP5055432B2 (ja) 2012-10-24
CN101868457A (zh) 2010-10-20
CN101868457B (zh) 2013-02-13
US20100286170A1 (en) 2010-11-11
KR20100059919A (ko) 2010-06-04
JP2010540462A (ja) 2010-12-24
EP2205596A1 (en) 2010-07-14
US8299267B2 (en) 2012-10-30
WO2009042694A1 (en) 2009-04-02
MX2010002938A (es) 2010-04-01

Similar Documents

Publication Publication Date Title
US8299267B2 (en) (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
US20080176939A1 (en) Compounds which inhibit beta-secretase activity and methods of use thereof
WO2012054510A1 (en) Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof
CA2697166A1 (en) Isophthalamide derivatives inhibiting betasecretase activity
US20080207527A1 (en) Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
US20120295894A1 (en) Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
US7659289B2 (en) Hydroxyethylene-based β-secretase inhibitors and use thereof
US20130059840A1 (en) Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
CA2756145A1 (en) Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
CN101198583A (zh) 抑制β-分泌酶(SECRETASE)活性的化合物及其使用方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140924